17,225 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Bank of Nova Scotia

Bank of Nova Scotia bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 17,225 shares of the medical equipment provider’s stock, valued at approximately $1,483,000.

Several other large investors have also modified their holdings of ZBH. Main Management ETF Advisors LLC lifted its holdings in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after buying an additional 112 shares during the period. Citizens National Bank Trust Department raised its holdings in shares of Zimmer Biomet by 17.6% in the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 141 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in Zimmer Biomet by 0.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock worth $1,831,000 after acquiring an additional 152 shares during the period. TD Private Client Wealth LLC boosted its position in Zimmer Biomet by 15.3% in the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock valued at $104,000 after buying an additional 153 shares during the last quarter. Finally, Leonteq Securities AG boosted its holdings in shares of Zimmer Biomet by 5.3% in the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock valued at $277,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZBH. Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Barclays reduced their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Canaccord Genuity Group lifted their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Trading Up 1.2%

ZBH opened at $101.41 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $107.85. The company has a market cap of $19.34 billion, a P/E ratio of 24.67, a PEG ratio of 2.72 and a beta of 0.45. The business’s 50-day simple moving average is $93.40 and its 200-day simple moving average is $91.31.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.